Research Analysts Set Expectations for BHST Q2 Earnings

BioHarvest Sciences Inc. (NASDAQ:BHST) – Analysts at HC Wainwright issued their Q2 2025 earnings per share estimates for shares of BioHarvest Sciences in a research note issued to investors on Tuesday, April 8th. HC Wainwright analyst A. Dayal forecasts that the company will post earnings per share of ($0.10) for the quarter. HC Wainwright has a “Buy” rating and a $14.00 price target on the stock. The consensus estimate for BioHarvest Sciences’ current full-year earnings is ($0.80) per share. HC Wainwright also issued estimates for BioHarvest Sciences’ Q3 2025 earnings at ($0.05) EPS and FY2029 earnings at $1.15 EPS.

Separately, Maxim Group began coverage on BioHarvest Sciences in a research note on Wednesday, December 18th. They set a “buy” rating and a $12.00 price target on the stock.

BioHarvest Sciences Stock Performance

Shares of NASDAQ BHST opened at $5.55 on Wednesday. The firm has a market capitalization of $91.16 million, a price-to-earnings ratio of -4.44 and a beta of 0.84. BioHarvest Sciences has a 1 year low of $5.40 and a 1 year high of $7.38. The stock’s 50 day moving average price is $5.74.

BioHarvest Sciences (NASDAQ:BHST) last issued its quarterly earnings results on Monday, March 31st. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.05). The firm had revenue of $7.17 million for the quarter, compared to analyst estimates of $7.24 million.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in BioHarvest Sciences stock. TD Waterhouse Canada Inc. purchased a new position in shares of BioHarvest Sciences Inc. (NASDAQ:BHST) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 12,042 shares of the company’s stock, valued at approximately $69,000. TD Waterhouse Canada Inc. owned about 0.07% of BioHarvest Sciences as of its most recent filing with the Securities and Exchange Commission (SEC).

About BioHarvest Sciences

BioHarvest Sciences Inc is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications.